A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries

NCT02637050 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 231

Last updated 2021-08-25

No results posted yet for this study

Summary

The aim of the registry is the assessment of the diagnosis and treatment of CTEPH (Chronic Thromboembolic Pulmonary Hypertension) in EMEA (Europe/Middle East/Africa) countries.

Conditions

  • Hypertension, Pulmonary

Interventions

OTHER

Standard of care

At the discretion of the attending physician.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-03
Primary Completion
2020-07-03
Completion
2020-09-17

Countries

  • Kazakhstan
  • Kyrgyzstan
  • Lebanon
  • Russia
  • Saudi Arabia
  • Turkey (Türkiye)

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02637050 on ClinicalTrials.gov